Evotec SE (EVO)
4.48
0.06 (1.36%)
At close: Feb 20, 2025, 3:59 PM
4.46
-0.45%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 4.43 |
| Market Cap | 1.59B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -8.78 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.69 |
| Volume | 75,748 |
| Avg. Volume (20D) | 125,623 |
| Open | 4.45 |
| Previous Close | 4.42 |
| Day's Range | 4.43 - 4.49 |
| 52-Week Range | 2.85 - 7.98 |
| Beta | undefined |
About EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly;...
Sector Healthcare
IPO Date Feb 5, 2004
Employees 5,007
Stock Exchange NASDAQ
Ticker Symbol EVO
Website https://www.evotec.com
Analyst Forecast
According to 2 analyst ratings, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $5.9, which is an increase of 31.70% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 months ago
-16.07%
Evotec shares are trading lower after Halozyme wit...
Unlock content with
Pro Subscription
3 months ago
+6.67%
Evotec shares are trading higher after Halozyme Therapeutics confirmed a cobmination offer.
